[CAS NO. 1333126-31-0] Azvudinehydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1333126-31-0]

Catalog

HY-19314A

Brand

MCE

CAS

1333126-31-0

DESCRIPTION [1333126-31-0]

Overview

MDL	-
Molecular Weight	322.68
Molecular Formula	C9H12ClFN6O4
SMILES	NC(C=CN1[C@@H]2O[C@@](N=[N+]=[N-])([C@H]([C@@H]2F)O)CO)=NC1=O.[H]Cl

For research use only. We do not sell to patients.

Summary

Azvudine (RO-0622) hydrochloride is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV , HBV and HCV . Azvudine hydrochloride exerts highly potent inhibition on HIV-1 (EC ₅₀ s ranging from 0.03 to 6.92 nM) and HIV-2 (EC ₅₀ s ranging from 0.018 to 0.025 nM). Azvudine hydrochloride inhibits NRTI-resistant viral strains ^[1] .

IC50 & Target

HIV-1

0.03-6.92 nM (EC ₅₀ )

HIV-2

0.018-0.02 nM (EC ₅₀ )

In Vitro

Azvudine (RO-0622) hydrochloride displays strong inhibition on wild-type HIV-1 _IIIB and HIV-1 _RF with an EC ₅₀ ranging from 30 to 110 pM. The EC ₅₀ values of Azvudine hydrochloride against HIV-1 _KM018 , HIV-1 _TC-1 and HIV-1 _{WAN T69N} are 6.92, 0.34 and 0.45 nM, respectively. Azvudine is sensitive to NRTIs-resistant strain HIV-1 _74V , PIs-resistant strains HIV-1 _{L10R/M46I/L63P/V82T/I84V} and HIV-1 _{RF V82F/184V} , and FIs-resistant strain pNL4-3 _{gp41 (36G) V38A/N42T} . The EC ₅₀ values of Azvudine hydrochloride against these resistant strains are 0.11, 0.14, 0.37 and 0.36 nM respectively ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04425772	HeNan Sincere Biotech Co., Ltd	COVID-19	June 12, 2020	Not Applicable
NCT05621993	Qianfoshan Hospital	COVID-19 Respiratory Infection	November 22, 2022
NCT05033145	HRH Pharmaceuticals Limited\|GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil\|Clinical Research Unit + High Complexity Center (CRU+HCC) + Galzu Institute	COVID-19	January 15, 2022	Phase 3
NCT04303598	HeNan Sincere Biotech Co., Ltd	HIV-infection+Aids	April 1, 2020	Phase 3
NCT04668235	HRH Pharmaceuticals Limited\|GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil\|UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE (UENF), Brazil	COVID-19	April 23, 2021	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 125 mg/mL ( 387.38 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0990 mL	15.4952 mL	30.9905 mL
5 mM	0.6198 mL	3.0990 mL	6.1981 mL
10 mM	0.3099 mL	1.5495 mL	3.0990 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 14.29 mg/mL (44.29 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

* All of the co-solvents are available by MCE.

References

[1] Wang RR, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One. 2014 Aug 21;9(8):e105617.